Tags: Drug.
Conatumumab (originally AMG 655) is a monoclonal antibody developed for the treatment of cancer. it is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2 death receptor 5) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL binding to and activating TR-2 thereby activating caspase cascades and inducing tumor cell apoptosis.